Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hikma Pharmaceuticals Plc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call


Wednesday, 13 Mar 2013 09:30am EDT 

Hikma Pharmaceuticals Plc announced that for fiscal 2013, it expects revenue growth of around 11%. The Company reported revenue of $1.109 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $1.230 billion for fiscal 2013.